Impact of 2 years of treatment with elexacaftor/tezacaftor/ivacaftor on longitudinal changes in structural lung disease in people with cystic fibrosis: results from the RECOVER trial
Paul G. McNally, Karen Lester, Rachel Cregan, B. Elnazir et autres
RATIONALE: Progressive structural lung disease (SLD) is a key hallmark of cystic fibrosis (CF). Elexacaftor/tezacaftor/ivacaftor (ETI) is associated with short-term improvements in SLD measured on chest computed tomography (CT). Longer-term changes in SLD outcomes with ETI are unknown. OBJECTIVES: Using multicenter standardized …
kn, ie, ca, nl, gb, us (code pays fourni par la source)
0 citations
Annals of the American Thoracic Society